TRK-250 (TRK-250) - 药物靶点：TGF-β1_在研适应症：特发性肺 …
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
A Nucleic Acid Drug, TRK-250, Receives Orphan Drug Designation*1 from ...
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
A Novel siRNA-Based Oligonucleotide, TRK-250, and Its Efficacy …
A Novel siRNA-Based Oligonucleotide, TRK-250, and Its Efficacy for Treatment of Idiopathic Pulmonary Fibrosis (IPF) Abstract Send to Citation Mgr
TRK-250 | Pulmonary Fibrosis Foundation
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
TRK-250（一种基于 siRNA 的新型寡核苷酸）在特发性肺纤维化患 …
目的：TRK-250 是一种新型单链寡核苷酸，带有由两个脯氨酸接头连接的人类转化生长因子-β1 靶向 siRNA 基序。 非临床研究表明 TRK-250 可能具有预防肺纤维化进展的功效。
A Phase I Study of TRK-250, a Novel siRNA-Based ... - PubMed
Purpose: TRK-250 is a novel single-stranded oligonucleotide carrying a human Transforming growth factor-beta 1-targeting siRNA motif tethered by two proline linkers. Nonclinical studies …
A Phase I Study of TRK-250, a Novel siRNA-Based …
2023年12月12日 · Nonclinical studies have shown that TRK-250 may have potency to prevent the progression of pulmonary fibrosis. Herein, a phase I study was conducted to investigate the …
TRK-250 在 特发性肺纤维化-临床试验注册中心-ICH GCP
2018年10月24日 · trk-250是一种核酸药物，通过在基因表达水平上选择性抑制转化生长因子-β1（tgf-β1）蛋白的表达来抑制肺纤维化的进展。 本研究是一项双盲、随机、安慰剂对照的 I 期 …
Toray Announces Initiation of Phase 1 Clinical Trial of TRK-250 for ...
TRK-250/BNC-1021 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) …
TRK-250 is a novel class of single-stranded oligonucleotide carrying a human TGF-β1-targeting siRNA motif tethered by two proline linkers. Nonclinical studies have demonstrated that TRK …